Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Reneo Pharmaceuticals stock

Learn how to easily invest in Reneo Pharmaceuticals stock.

Reneo Pharmaceuticals, Inc
NASDAQ: RPHM - USD
BIOTECHNOLOGY
$8.52
-$0.15 (-1.78%)

Reneo Pharmaceuticals, Inc is a biotechnology business based in the US. Reneo Pharmaceuticals shares (RPHM) are listed on the NASDAQ and all prices are listed in US Dollars. Reneo Pharmaceuticals employs 16 staff and has a market cap (total outstanding shares value) of 0.00.

How to buy shares in Reneo Pharmaceuticals

  1. Compare share trading platforms.Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – RPHM – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Reneo Pharmaceuticals stock price (NASDAQ: RPHM)

Use our graph to track the performance of RPHM stocks over time.

Reneo Pharmaceuticals shares at a glance

Information last updated 2021-07-23.
52-week range$7.63 - $17.18
50-day moving average $9.47
200-day moving average $10.77
Wall St. target price$31.33
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) N/A

Buy Reneo Pharmaceuticals shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
Sofi Invest
Stocks, ETFs, Cryptocurrency
N/A
0%
Get one free stock worth up to $1,000
Open an account
A free way to invest in stocks, ETFs and crypto.
Webull
Stocks, Options, ETFs
$0
0%
Get one free stock valued between $3.00 and $300 when you open an account, one more with a deposit
Open an account
Margin financing rates start at 3.99%. No monthly subscription fees for margin.
Public
Stocks, ETFs
N/A
$0 per month
Download and sign up with Public.com; approved accounts receive a free stock slice worth up to $70, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.
J.P. Morgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$0 + $0.65/contract
0%
N/A
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs
$0
0%
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Moomoo
Stocks, Options, ETFs
$0
$0 per year
N/A
Trade stocks on the US, Hong Kong, Shanghai and Shenzhen markets.
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Reneo Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Reneo Pharmaceuticals financials

Gross profit TTM $0
Return on assets TTM -30.28%
Return on equity TTM -53.23%
Profit margin 0%
Book value N/A
Market capitalisation $216.1 million

TTM: trailing 12 months

Shorting Reneo Pharmaceuticals shares

There are currently 1.2 million Reneo Pharmaceuticals shares held short by investors – that's known as Reneo Pharmaceuticals's "short interest". This figure is 45.2% up from 805,991 last month.

There are a few different ways that this level of interest in shorting Reneo Pharmaceuticals shares can be evaluated.

Reneo Pharmaceuticals's "short interest ratio" (SIR)

Reneo Pharmaceuticals's "short interest ratio" (SIR) is the quantity of Reneo Pharmaceuticals shares currently shorted divided by the average quantity of Reneo Pharmaceuticals shares traded daily (recently around 112089.08045977). Reneo Pharmaceuticals's SIR currently stands at 10.44. In other words for every 100,000 Reneo Pharmaceuticals shares traded daily on the market, roughly 10440 shares are currently held short.

To gain some more context, you can compare Reneo Pharmaceuticals's short interest ratio against those of similar companies.

However Reneo Pharmaceuticals's short interest can also be evaluated against the total number of Reneo Pharmaceuticals shares, or, against the total number of tradable Reneo Pharmaceuticals shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Reneo Pharmaceuticals's short interest could be expressed as 0.05% of the outstanding shares (for every 100,000 Reneo Pharmaceuticals shares in existence, roughly 50 shares are currently held short) or 0.1267% of the tradable shares (for every 100,000 tradable Reneo Pharmaceuticals shares, roughly 127 shares are currently held short).

A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against Reneo Pharmaceuticals.

Find out more about how you can short Reneo Pharmaceuticals stock.

Reneo Pharmaceuticals share dividends

We're not expecting Reneo Pharmaceuticals to pay a dividend over the next 12 months.

Reneo Pharmaceuticals overview

Reneo Pharmaceuticals, Inc. , a clinical stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as well as in Phase 1b clinical trial in patients with long-chain fatty acid oxidation disorders and glycogen storage disease type V. The company was incorporated in 2014 and is headquartered in San Diego, California. .

Stocks similar to Reneo Pharmaceuticals

Frequently asked questions

What percentage of Reneo Pharmaceuticals is owned by insiders or institutions?
Currently 3.072% of Reneo Pharmaceuticals shares are held by insiders and 60.898% by institutions.
How many people work for Reneo Pharmaceuticals?
Latest data suggests 16 work at Reneo Pharmaceuticals.
When does the fiscal year end for Reneo Pharmaceuticals?
Reneo Pharmaceuticals's fiscal year ends in December.
Where is Reneo Pharmaceuticals based?
Reneo Pharmaceuticals's address is: 12230 El Camino Real, San Diego, CA, United States, 92130

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site